The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
Promega's technology will be part of a larger portfolio of research products aimed at supporting oncology drug and clinical trial development.
The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
Researchers are using Bio-Rad's droplet digital PCR technology to validate seven ctDNA biomarkers that may predict melanoma recurrence.
The two companies have established a broad framework that will enable them to collaborate on specific projects to develop NGS-based companion diagnostics.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.
The firm's NGS-based Notch 1 mutation detection test will be used to enroll patients in clinical trials.
Researchers describe a way to share data while keeping it secure, Agence France Presse reports.
In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.
India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.
A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.